Implications of the 5-year CR FIRST trial

Neurology

Volumn 50, Issue 6 SUPPL.6, 1998, Pages

  Capildeo, Rudy ^a,b,c  

^a OLDCHURCH HOSPITAL   (United Kingdom)

^b Basildon and Thurrock General Hospitals   (United Kingdom)

^c Red Cottage   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; AGED; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG BLOOD LEVEL; DYSKINESIA; FEMALE; HUMAN; INCIDENCE; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SUSTAINED RELEASE PREPARATION;

EID: 0031840547     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.6_suppl_6.s15     Document Type: Review

References (10)

1. Barbeau A, Roy M. Ten-year results of treatment with levodopa plus benserazide in Parkinson's disease. In: Rose FC, Capildeo R, eds. Research progress in Parkinson's disease. Tunbridge Wells, UK: Pitman Medical, 1981:241-247.
2. Marsden CD, Parkes JD, Rees JE. A year's comparison of treatment of patients with Parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 1973;2:1459-1462.
3. Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias: possible treatment by increasing the daily doses of levodopa. Arch Neurol 1978;35:261-263.
4. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;1:345-349.
5. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36:1528-1530.
6. Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996;93:14-20.
7. Yahr MD. Long-term levodopa in Parkinson's disease [letter]. Lancet 1977;1:706-707.
8. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984;11(suppl 1):200-205.
9. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986;43:402-405.
10. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. The CR FIRST Study Group. Eur Neurol 1997;37:23-27.